Biofrontera (BFRI) News
NASDAQ: BFRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.97+0.0512 (+5.57%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BFRI news summary
We found 2 recent headlines mentioning Biofrontera (BFRI): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. BFRI is making an outsized move today, up 5.57% at $0.97, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis Use", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Biofrontera headlines
- Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis Use(RTTNews) - On Thursday, Biofrontera Inc. (BFRI) said it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking to expand the approved use of Ameluz in combination with…Nasdaq
- Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full BodySubmission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocolGlobeNewswire